WO2017049328A1 - A chewable gum composition - Google Patents
A chewable gum composition Download PDFInfo
- Publication number
- WO2017049328A1 WO2017049328A1 PCT/ZA2016/050033 ZA2016050033W WO2017049328A1 WO 2017049328 A1 WO2017049328 A1 WO 2017049328A1 ZA 2016050033 W ZA2016050033 W ZA 2016050033W WO 2017049328 A1 WO2017049328 A1 WO 2017049328A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gum composition
- chewable gum
- plant extract
- chewable
- glycyrrhiza glabra
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Definitions
- the invention relates to a chewable gum composition.
- BACKGROUND ART Recurrent Aphtous Stomatitis (RAS), Recurrent Aphtous Ulceration (RAU), canker sores, aphthae or aphtous ulcers is an inflammatory condition of unknown aetiology characterised by painful recurrent, single or multiple ulcerations of the oral mucosa.
- Canker sores are the most common of all non - traumatic ulcerative and vesicular lesions of the oral cavity (Natah et al., 2004). The exact cause of canker sores remains unkown, hence the difficulty in determining a curative treatment.
- the current primary option for treating this condition includes oral topical dosage forms such as pastes, gels, mouthwashes, creams and ointments.
- a downside of these conventional medicines lies in the fact that they are usually easily removed from the site of action due to tongue and saliva movement, and in addition, are difficult to apply when the ulcer is located in the arched opening at the back of the mouth leading to the pharynx (Patel, Liu & Brown, 201 1 ).
- Another disadvantange is the quick release and sudden termination of active substance availability at the required site of action.
- a chewable gum composition which includes:- a Salvia officinalis plant extract;
- a carrier for carrying and releasing the plant extracts when chewing the chewable gum composition.
- percentage fraction will be understood to mean weight by weight (W/W) percentages.
- any portion of the leaves and / or roots and / or stems of Salvia officinalis may be used to manufacture the Salvia officinalis based plant extract.
- the Salvia officinalis plant extract may have an extract factor and / or strength of 5:1 meaning that 5 units of Salvia officinalis plant material is used to produce 1 unit of Salvia officinalis plant extract.
- the Salvia officinalis plant extract may comprise up to 35 % of the chewable gum composition.
- the Salvia officinalis plant extract may comprise between 8 mg and 450 mg of the chewable gum composition.
- the Salvia officinalis plant extract may contain rosmarinic acid and caffeic acid.
- the Salvia officinalis plant extract may contain about 0.105% rosmarinic acid and 0.0126% caffeic acid when using a 5:1 Salvia officinalis plant extract. Any portion of the leaves and / or roots and / or stems of Glycyrrhiza glabra may be used to manufacture the Glycyrrhiza glabra based plant extract.
- the Glycyrrhiza glabra plant extract may have an extraction and / or processed factor of 4:1 meaning that 4 units of Glycyrrhiza glabra plant material is used to produce 1 unit of Glycyrrhiza glabra plant extract.
- the Glycyrrhiza glabra plant extract may comprise up to 20 % of the chewable gum composition.
- the Glycyrrhiza glabra plant extract may comprise between 4 mg and 250 mg of the chewable gum composition.
- the Glycyrrhiza glabra plant extract may contain glycyrrhizic acid.
- the Glycyrrhiza glabra plant extract may contain about 2.383 % glycyrrhizic acid when using a 4:1 Glycyrrhiza glabra plant extraction.
- the rosmarinic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
- the rosmarinic acid may comprise up to 1 % of the chewable gum composition.
- the caffeic acid may comprise between 0.01 mg and 1 mg of the chewable gum composition.
- the caffeic acid may comprise up to 1 % of the chewable gum composition.
- the glycyrrhizic acid may comprise between 0.1 mg and 6 mg of the chewable gum composition.
- the glycyrrhizic acid may comprise up to 3 % of the chewable gum composition.
- the carrier may be in the form of any suitable excipient for allowing the sustained and / or modified release of the plant extracts when chewing the chewable gum composition.
- the carrier may be in the form of a chewable gum.
- the carrier may comprise any one or more of the group consisting of a gum base, an elastomer, an emulsifier, a filler, a wax, an antioxidant, a softener, a sweetener, a food colouring and / or flavouring agent.
- the percentage fraction of carrier : Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be in the range of 49 % - 99 % : 0.5 % - 32 % : 0.5 % - 20 %.
- the percentage fraction of carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract in the chewable gum composition may be about 90% : 6.4 % : 3.6 %
- the chewable gum composition may further also include any one or more pharmaceutical excipients commonly used for formulating a solid oral dosage form, such as a chewable tablet, selected from the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavour absorbing agent and a flavourant.
- a pharmaceutical excipients commonly used for formulating a solid oral dosage form such as a chewable tablet, selected from the group consisting of a glidant, a lubricant, a binder, a taste masking agent, a flavour absorbing agent and a flavourant.
- the glidant in turn may be selected from any one or more of the group consisting of talc (magnesium hydrous silicate), and colloidal silicon dioxide.
- the lubricant may be selected from any one or more of the group consisting of magnesium stearate, stearic acid, sodium stearyl fumerate and sodium behenate.
- the binder may be selected from any one or more of the group consisting of hydroxypropylcellulose, methylcellulose, hypromellose, polyvinylpyrrolidone (povidone) and copovidone.
- the taste masking agent may be in the form of citric acid monohydrate.
- the flavour absorbing agent may be in the form of calcium carbonate.
- the flavourant may be selected from any one or more of the group consisting of wild cherry and spearmint liquid.
- the percentage fraction of the carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be in the range of 40 - 90% : 0.5 - 30 % : 0.5 - 20 % : 1 - 5 % : 0.1 - 3 % : 1 - 10 % : 0,1 - 3 % : 1 - 5 % : 0.1 - 5 %.
- the percentage fraction of the carrier Salvia officinalis based plant extract :
- Glycyrrhiza glabra based plant extract glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 78.27% : 5.55 % : 3.26 % : 2.24 % : 0.25 % : 5 % : 0.3 % : 2.25 % : 2.88 %.
- the weight ratio of the carrier Salvia officinalis based plant extract : Glycyrrhiza glabra based plant extract : glidant : lubricant : binder : taste masking agent : flavourant absorbing agent : flavourant in the chewable gum composition may be 1 173.88 mg : 83.33 mg : 48.93 mg : 33.69 mg : 3.75 mg : 75 mg : 4.5 mg : 33.69 mg : 43.23 mg.
- the chewable gum composition may be in the form of a solid oral dosage form, such as a conventional chewable tablet.
- the composition may be film and / or sugar coated to enhance the stability / and or organoleptic properties thereof.
- the film coating may comprise any commonly used excipient used in the pharma industry for coating tablets, such as hydroxypropyl methylcellulose (HPMC).
- HPMC hydroxypropyl methylcellulose
- the film coating may comprise between 1 % and 6 % of the total dosage mass.
- a chewable gum composition presented preferably in tablet form to a user, for treating oral canker sores.
- the delivery site having a fairly large contact surface leading to increased quantities of drug being absorbed at a faster rate of absorption.
- the Applicant considers the invention advantageous in that a chewable gum composition in tablet form is provided for releasing Glycyrrhiza glabra and Salvia officinalis plant extracts and thereby the active ingredients rosmarinic acid, caffeic acid and glycyrrhizic in the oral cavity when chewing the said composition for treating conditions such as oral canker sores.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA201506844 | 2015-09-16 | ||
ZA2015/06844 | 2015-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017049328A1 true WO2017049328A1 (en) | 2017-03-23 |
Family
ID=57868437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ZA2016/050033 WO2017049328A1 (en) | 2015-09-16 | 2016-09-16 | A chewable gum composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017049328A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3923984A (en) * | 1974-02-11 | 1975-12-02 | Atha Beatrice Z | Shelf stable multi-use composition, preparation and use |
NL9300683A (en) * | 1993-04-21 | 1994-11-16 | Frans De Boer | Liquorice wool |
WO2001012144A1 (en) * | 1999-08-19 | 2001-02-22 | Optiva Corporation | Gums containing antimicrobial agents |
US6231896B1 (en) * | 2000-09-08 | 2001-05-15 | The Goodyear Tire & Rubber Company | Chewing gum base stabilized with carnosic acid |
EP1236466A1 (en) * | 2001-02-28 | 2002-09-04 | Efrat Biopolymers Ltd. | Absorbable solid compositions for topical treatment of oral mucosal disorders |
US20080274179A1 (en) * | 2007-05-02 | 2008-11-06 | Chantal Bergeron | Supercritical CO2 liquorice extract and products made there from |
US20080317681A1 (en) * | 2003-07-11 | 2008-12-25 | Petros Gebreselassie | Compositions containing a stain removing complex, and methods of making and using the same |
US20120251462A1 (en) * | 2011-04-04 | 2012-10-04 | Cognis Ip Management Gmbh | Agent For Smoker Dehabituation |
-
2016
- 2016-09-16 WO PCT/ZA2016/050033 patent/WO2017049328A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3923984A (en) * | 1974-02-11 | 1975-12-02 | Atha Beatrice Z | Shelf stable multi-use composition, preparation and use |
NL9300683A (en) * | 1993-04-21 | 1994-11-16 | Frans De Boer | Liquorice wool |
WO2001012144A1 (en) * | 1999-08-19 | 2001-02-22 | Optiva Corporation | Gums containing antimicrobial agents |
US6231896B1 (en) * | 2000-09-08 | 2001-05-15 | The Goodyear Tire & Rubber Company | Chewing gum base stabilized with carnosic acid |
EP1236466A1 (en) * | 2001-02-28 | 2002-09-04 | Efrat Biopolymers Ltd. | Absorbable solid compositions for topical treatment of oral mucosal disorders |
US20080317681A1 (en) * | 2003-07-11 | 2008-12-25 | Petros Gebreselassie | Compositions containing a stain removing complex, and methods of making and using the same |
US20080274179A1 (en) * | 2007-05-02 | 2008-11-06 | Chantal Bergeron | Supercritical CO2 liquorice extract and products made there from |
US20120251462A1 (en) * | 2011-04-04 | 2012-10-04 | Cognis Ip Management Gmbh | Agent For Smoker Dehabituation |
Non-Patent Citations (5)
Title |
---|
"THE CR100 SYSTEM. ÖUSE OF CONTROLLED RELEASE FLAVOURS IN CHEWING GUM", CONFECTIONERY PRODUCTION, SPECIALISED PUBLICATIONS LTD., SURREY, GB, vol. 61, no. 4, 1 April 1995 (1995-04-01), pages 308 - 310, XP000512428, ISSN: 0010-5473 * |
C MESSIER ET AL: "Licorice and its potential beneficial effects in common oro-dental diseases", ORAL DISEASES, vol. 18, no. 1, 18 August 2011 (2011-08-18), pages 32 - 39, XP055041720, ISSN: 1354-523X, DOI: 10.1111/j.1601-0825.2011.01842.x * |
DONG ET AL: "Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 45, no. 12, 23 October 2007 (2007-10-23), pages 2470 - 2478, XP022310495, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2007.05.031 * |
NASSIRI ASL M ET AL: "Review of pharmacological effects of glycyrrhiza sp. and its bioactive compounds", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 22, no. 6, 1 June 2008 (2008-06-01), pages 709 - 724, XP002523763, ISSN: 0951-418X, [retrieved on 20080429], DOI: 10.1002/PTR.2362 * |
SCULLY; GORSKY; LOZADA, NUR, 2003 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1236466B1 (en) | Solid self-adhesive compositions for topical treatment of oral mucosal disorders | |
RU2382637C2 (en) | Pharmaceutical composition for peroral introduction in form of particles with calculated time of release and quickly decomposing tablets containing said composition | |
JP6294479B2 (en) | Oral dispersible film | |
RU2450819C2 (en) | Herbal compositions for treating oral diseases | |
US20090263467A1 (en) | Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments | |
EP3328409B1 (en) | Composition for the increase of humoral secretion | |
WO2019199260A2 (en) | Formulations comprising herbal extracts | |
US20130039981A1 (en) | Quick Dissolving, Long Acting Zinc Therapeutic Formulations | |
JP6098634B2 (en) | Fast disintegrating tablets | |
US20120015021A1 (en) | Anti-appetite adhesive compositions | |
US10335443B2 (en) | Orodispersible film | |
ES2922243T3 (en) | Composition to prevent headaches | |
RU2311176C2 (en) | Ambroxol for treating pains in oral cavity and pharynx | |
JP5284070B2 (en) | Oral mucosa patch preparation | |
EP1463488B1 (en) | Pharmaceutical composition comprising skimmed milk powder | |
JP5032003B2 (en) | Analgesic and anti-inflammatory lozenges for oral mucosa | |
KR20150136540A (en) | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx | |
WO2017049328A1 (en) | A chewable gum composition | |
KR20150048890A (en) | Pharmaceutical compositions comprising flurbiprofen | |
Gupta et al. | An overview of mouth dissolving films: Formulation aspects | |
US7985430B2 (en) | Solid mucoadhesive composition | |
EP2959889A1 (en) | Orally disintegrating formulations of loxoprofen | |
JP2009507850A5 (en) | ||
JP6315741B2 (en) | Composition for oral cavity containing NSAIDs or heparins | |
Menra et al. | A REVIEW ON BUCCAL FILM: AN INOVATIVE DOSAGE FORM. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16829391 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16829391 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16829391 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16829391 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31.01.2019) |